Insider trade

CEO sold ~$490K of CYTK shares in the open market

Traded Apr 15, 2026 · Filed Apr 15, 2026

Why it stands out

The boss of Cytokinetics sold $490K of Cytokinetics shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$490,350

Shares × reported transaction price

Timing vs results

50 days after results of Feb 24, 2026, 20 days before results of May 5, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Filing box checked: sold under a Rule 10b5-1 plan

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+0.1%	+1.0%	−0.9%
30 days	+14.9%	+5.3%	+9.7%
90 days	+26.3%	+7.6%	+18.7%

Past results only. Not a forecast.

Automatic sale5mo ago

5mo ago

Derivative exercise or conversion — not an open-market buy.

Automatic sale5mo ago